DAISY – Specific Aim 3

Delivery of Antiretrovirals via Implantable System for Young Children (DAISY) Specific Aim 3.

Rationale

South Africa reports one of the highest populations of HIV-infected young children and of the 55% of children that receive ART only 67% are virally suppressed. Adherence and retention in care are affected by multiple challenges with formulation and dosages for children, including poor palatability of drugs, high pill burden, and difficulty in swallowing. Simplified dosing regimens and long-acting (LA) ART formulations are needed to improve treatment success for children who face a lifetime of ART. Delivery of ART via implantable system for young children (DAISY) is one such formulation currently in development. Integrated research on product development and end-user preferences is critical for successful product development. For technology optimization and future implementation of the DAISY into clinical practice, research is needed on end-users’ perspectives on (1) acceptability and preferred characteristics of the DAISY system for pediatric treatment, (2) considerations for future implementation within the existing health care system in SA, and (3) biodegradability of the inserted implants.

Investigators

• Lee Fairlie, Wits RHI
• Elizabeth Montgomery, RTI International
• Fiona Scorgie, Wits RHI

Latest Update:

April 2024

For more about DAISY – Specific Aim 3 please email rhicomms@wrhi.ac.za